Post-Operative Cataract Surgery Inflammation Treatment Global Market Report 2025

The post-operative cataract surgery inflammation treatment market size has grown strongly in recent years. It will grow from $4.44 billion in 2024 to $4.79 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth during the historic period can be attributed to an aging population, greater awareness of post-operative complications, a higher prevalence of ocular disorders, increased demand for effective treatments, and advancements in surgical techniques and lens implants.

The post-operative cataract surgery inflammation treatment market size is expected to see strong growth in the next few years. It will grow to $6.4 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The projected growth in the forecast period can be attributed to better access to treatment for traumatic injuries, increased availability of advanced drug delivery systems, the growing use of combination therapies, a rise in the incidence of diabetes and ocular comorbidities, and the expanding use of personalized medicine in ophthalmology. Key trends during this period include advancements in surgical techniques, the adoption of cutting-edge drug delivery systems, the development of combination therapies, innovative anti-inflammatory treatments, and the integration of AI and digital health.

The increasing occurrence of traumatic injuries is expected to drive the growth of the post-operative cataract surgery inflammation treatment market. Traumatic injuries are sudden physical harm caused by external forces such as accidents, falls, violence, or impacts from sports, and can range from minor cuts to severe fractures, burns, brain injuries, and spinal damage. Factors contributing to the rise in traumatic injuries include more road traffic accidents, workplace hazards, sports-related incidents, violence, natural disasters, and an aging population more susceptible to falls. Post-operative cataract surgery inflammation treatments help manage traumatic injuries by reducing ocular inflammation, alleviating pain, and preventing complications that could hinder visual recovery. For example, in December 2023, the Bureau of Labor Statistics, a US-based government agency, reported that fatal work injuries in the United States rose to 5,486 in 2022, a 5.7% increase from 5,190 in 2021, highlighting a significant rise in industrial accidents. This upward trend further emphasizes the growing demand for post-operative cataract surgery inflammation treatments.

Leading companies in the post-operative cataract surgery inflammation treatment market are focused on developing innovative approaches such as combination therapies to improve treatment outcomes and enhance patient recovery. Combination therapy involves using two or more medications or treatment strategies together to achieve better therapeutic results, helping reduce inflammation, prevent infection, and support faster recovery. For example, in August 2022, Santen Pharmaceutical Co. Ltd., a Japan-based company, introduced Ducressa in the UK and Ireland to improve post-cataract surgery care. This fixed-dose combination of levofloxacin and dexamethasone helps prevent infections and reduce inflammation, ensuring more effective recovery. The treatment is designed to be followed with a seven-day regimen, enhancing patient convenience and adherence.

In September 2024, Armistice Capital LLC, a US-based home healthcare service company, acquired Eyenovia Inc. for an undisclosed amount. With this acquisition, Armistice Capital LLC aims to increase its influence over Eyenovia’s strategic direction and capitalize on potential growth opportunities within the ophthalmic sector. Eyenovia Inc., a US-based pharmaceutical company, specializes in treating post-operative inflammation and pain after ocular surgery using clobetasol.

Major players in the post-operative cataract surgery inflammation treatment market are Pfizer Inc., Merck & Co. Inc., Novartis AG., Alcon Inc, Sun Pharmaceutical Industries Limited, Bausch & Lomb Incorporated, Santen Pharmaceutical Co. Ltd., Mallinckrodt plc, Bio-Tissue Inc., Ocular Therapeutix Inc., Oculis Holding AG, Senju Pharmaceutical Co. Ltd., NTC Srl, EyePoint Pharmaceuticals Inc, ImprimisRx LLC, Eyenovia Inc., Formosa Pharmaceuticals Inc, Nicox S.A., Surface Ophthalmics Inc., VivaVision Biotech Inc.

North America was the largest region in the post-operative cataract surgery inflammation treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in post-operative cataract surgery inflammation treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the post-operative cataract surgery inflammation treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Post-operative cataract surgery inflammation treatment involves medical interventions designed to manage inflammation and discomfort following cataract surgery. These medications help control inflammation, reduce the risk of complications such as rebound iritis and pseudophakic cystoid macular edema (PCME), and support a quicker recovery.

The primary drug classes for treating post-operative inflammation following cataract surgery include bromfenac, indomethacin, diclofenac, flurbiprofen, and nepafenac. Bromfenac, a powerful NSAID used in ophthalmology, helps alleviate post-operative pain and inflammation by inhibiting COX-1 and COX-2 enzymes. These medications are available in various formulations, including oral and injectable forms, and are distributed through diverse channels such as hospital pharmacies, online pharmacies, and retail pharmacies.

The post-operative cataract surgery inflammation treatment market research report is one of a series of new reports that provides post-operative cataract surgery inflammation treatment market statistics, including the post-operative cataract surgery inflammation treatment industry global market size, regional shares, competitors with the post-operative cataract surgery inflammation treatment market share, detailed post-operative cataract surgery inflammation treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the post-operative cataract surgery inflammation treatment industry. This post-operative cataract surgery inflammation treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The post-operative cataract surgery inflammation treatment market consists of sales of corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and anti-inflammatory medications. Values in this market are 'factory gate' values, meaning the value of goods sold by manufacturers, whether to other entities (including wholesalers, distributors, or directly to end customers) or downstream manufacturers. The value of goods includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.